Beatrice Osumili
7PUBLICATIONS
17CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Mar 02, 2026
Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK.Naresh Kanumilli, Beatrice Osumili, Jerome Evans
|Feb 07, 2025
Correction to: The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan.Toshihiko Aranishi, Ataru Igarashi, Kazuo Hara
|Dec 21, 2024
The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan.Toshihiko Aranishi, Ataru Igarashi, Kazuo Hara
|Nov 02, 2024
Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes Mellitus in France and Italy: A Retrospective Cohort Study.Swarna Khare, Beatrice Osumili, Nele Debackere
|Mar 29, 2023
The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 Diabetes.Heather L Gelhorn, Beatrice Osumili, Katelyn Brown
|Feb 02, 2022
The PRIME Type 2 Diabetes Model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitus.Richard F Pollock, Kirsi Norrbacka, Kristina S Boye
Pageof 2
Frequent Collaborators
4 joint publications
Barnaby Hunt
2 joint publications
Alice Minghetti
2 joint publications
Masakazu Takeuchi
2 joint publications
Toshihiko Aranishi
2 joint publications
Ataru Igarashi
2 joint publications
Zhihong Cai
2 joint publications
Manaka Sato
1 joint publications
Juliette Cattin
1 joint publications
Beth D Mitchell
1 joint publications
Richard F Pollock
